Building the Future of Cancer T Cell Immunotherapy

CAR/TCR Technology

Latest News

Collaboration

eACT™ (engineered Autologous Cell Therapy) is a promising innovation in immunotherapy encompassing T cells manufactured ex vivo, that are genetically redirected against cancerous cells.  

eACT™ unleashes and focuses the full potential of the immune system against cancer, under the paradigm of personalized medicine.

April 2 2014
Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer
March 31 2014

Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product

Kite Pharma is partnered with the National Cancer Institute (NCI) through a Cooperative Research and Development Agreement (CRADA).